Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Families and children news

Show

From To
Yes, HIV-Positive Men Can Become Fathers. Here's Two Providers Who Help Them

In HIV, we pay a lot of attention to parenthood -- but mostly from the perspective of ending mother-to-child transmission. Even then, the public health message is often mostly about the baby, not the health and well-being of the mother. But almost nowhere do we have deep discussions about reproductive options for HIV-positive men, particularly cisgender straight men.

Published
18 June 2018
From
TheBody.com
Nigeria has more HIV-infected babies than anywhere in the world. It’s a distinction no country wants

At a time when rates of mother-to-child transmission of HIV have plummeted, even in far poorer countries, Nigeria accounted for 37,000 of the world’s 160,000 new cases of babies born with HIV in 2016.

Published
13 June 2018
From
Science
The End of AIDS: Far from Over

The tools exist. HIV/AIDS can be treated and contained. But in many communities, social, political and economic obstacles get in the way. There, the epidemic is far from over. PBS Newshour reports from Russian, Nigeria and Florida.

Published
12 June 2018
From
PBS NewsHour
FDA says Prezcobix should not be given to pregnant women

Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.

Published
11 June 2018
From
Healio (requires free registration)
Children born with HIV on treatment experience next-to-no developmental set-backs at the age of 5

New data on the impact of different treatment strategies on the neuro-development of young children living with HIV has been released, showing normal development in all areas apart from visual perception.

Published
25 May 2018
From
AVERT
BHIVA statement on Potential Safety Signal in Infants Born to Women Conceiving on Dolutegravir

The BHIVA HIV in Pregnancy Guidelines Writing group makes the following recommendations: all women wishing to conceive should be started on folic acid 5mg OD regardless of their cART regimen; all women commencing DTG should have a negative pregnancy test prior to initiation and ongoing method of contraception documented; we advise a review of all patient records of women aged up to 50yo on DTG with regards to conception plans, documented method of contraception and current pregnancy status; we recommend that women at risk of pregnancy be contacted by their clinic to discuss the DTG safety report, which should be clearly documented, and the woman seen in person if pregnant.

Published
23 May 2018
From
British HIV Association
Dolutegravir may cause birth defects, European Medicines Agency warns

Regulatory agencies in the United States and European Union have warned that women with HIV who can become pregnant should not use the integrase inhibitor

Published
21 May 2018
By
Keith Alcorn
Potential safety issue affecting women living with HIV using dolutegravir at the time of conception

WHO advises that countries and ministries follow the existing 2016 WHO Consolidated ARV Guidelines, and consider the following: Pregnant women who are taking DTG should not stop their ARV therapy and should speak with their health provider for additional guidance. If other first‐line ARVs cannot be used in women of childbearing age, DTG may be considered in cases where consistent contraception can be assured.

Published
21 May 2018
From
World Health Organization
Why the Dolutegravir Pregnancy Warning is Important — and What We Should Do Now

Based on the widespread and growing use of DTG-based regimens globally, these data on the potential risks of becoming pregnant while receiving DTG have immediate and broad clinical relevance.

Published
21 May 2018
From
NEJM Journal Watch
New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

The European Medicines Agency (EMA) is evaluating preliminary results from a study which found 4 cases of birth defects such as spina bifida (malformed spinal cord) in babies born to mothers who became pregnant while taking dolutegravir. While EMA is assessing the new evidence, dolutegravir should not be used in women seeking to become pregnant.

Published
21 May 2018
From
European Medicines Agency
← First12345...107Next →
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.